Brooks O'Neil
Stock Analyst at Lake Street
(1.03)
# 3,882
Out of 5,040 analysts
36
Total ratings
32.35%
Success rate
-12.08%
Average return
Main Sectors:
Stocks Rated by Brooks O'Neil
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Downgrades: Hold | $75 → $12 | $14.66 | -18.14% | 2 | Aug 11, 2025 | |
| RCEL AVITA Medical | Maintains: Buy | $14 → $8 | $4.02 | +99.00% | 7 | Aug 11, 2025 | |
| LFMD LifeMD | Maintains: Buy | $18 → $14 | $6.23 | +124.72% | 3 | Aug 6, 2025 | |
| PIII P3 Health Partners | Maintains: Buy | $50 → $20 | $8.88 | +125.23% | 2 | Apr 21, 2025 | |
| SRDX Surmodics | Upgrades: Buy | $43 | $27.47 | +56.53% | 4 | Mar 7, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $89.01 | +23.58% | 2 | Feb 28, 2025 | |
| BBNX Beta Bionics | Initiates: Buy | $30 | $20.02 | +49.89% | 1 | Feb 24, 2025 | |
| SMLR Semler Scientific | Maintains: Buy | $40 → $71 | $22.76 | +211.95% | 1 | Jan 24, 2025 | |
| LFVN LifeVantage | Initiates: Buy | $26 | $8.82 | +194.78% | 1 | Dec 19, 2024 | |
| HROW Harrow | Maintains: Buy | $45 → $55 | $39.04 | +40.88% | 3 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $15.89 | +13.28% | 4 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $4.11 | +21.65% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.64 | +80.72% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $24.69 | +5.31% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $0.56 | +1,872.39% | 1 | Apr 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $128 | $31.37 | +306.44% | 1 | Sep 15, 2020 |
Tandem Diabetes Care
Aug 11, 2025
Downgrades: Hold
Price Target: $75 → $12
Current: $14.66
Upside: -18.14%
AVITA Medical
Aug 11, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.02
Upside: +99.00%
LifeMD
Aug 6, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $6.23
Upside: +124.72%
P3 Health Partners
Apr 21, 2025
Maintains: Buy
Price Target: $50 → $20
Current: $8.88
Upside: +125.23%
Surmodics
Mar 7, 2025
Upgrades: Buy
Price Target: $43
Current: $27.47
Upside: +56.53%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $89.01
Upside: +23.58%
Beta Bionics
Feb 24, 2025
Initiates: Buy
Price Target: $30
Current: $20.02
Upside: +49.89%
Semler Scientific
Jan 24, 2025
Maintains: Buy
Price Target: $40 → $71
Current: $22.76
Upside: +211.95%
LifeVantage
Dec 19, 2024
Initiates: Buy
Price Target: $26
Current: $8.82
Upside: +194.78%
Harrow
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $39.04
Upside: +40.88%
Sep 3, 2024
Maintains: Buy
Price Target: $32 → $18
Current: $15.89
Upside: +13.28%
Jun 28, 2024
Initiates: Buy
Price Target: $5
Current: $4.11
Upside: +21.65%
Mar 7, 2024
Initiates: Buy
Price Target: $12
Current: $6.64
Upside: +80.72%
Feb 15, 2023
Maintains: Buy
Price Target: $20 → $26
Current: $24.69
Upside: +5.31%
Apr 8, 2022
Initiates: Buy
Price Target: $11
Current: $0.56
Upside: +1,872.39%
Sep 15, 2020
Initiates: Buy
Price Target: $128
Current: $31.37
Upside: +306.44%